136 related articles for article (PubMed ID: 3179468)
1. (Pyridoxylated hemoglobin)-(polyoxyethylene) conjugate solution as blood substitute for normothermic whole body rinse-out.
Agishi T; Funakoshi Y; Honda H; Yamagata K; Kobayashi M; Takahashi M
Biomater Artif Cells Artif Organs; 1988; 16(1-3):261-70. PubMed ID: 3179468
[TBL] [Abstract][Full Text] [Related]
2. In vivo evaluation of a pyridoxylated-hemoglobin-polyoxyethylene conjugate.
Matsushita M; Yabuki A; Malchesky PS; Harasaki H; Nosé Y
Biomater Artif Cells Artif Organs; 1988; 16(1-3):247-60. PubMed ID: 3179467
[TBL] [Abstract][Full Text] [Related]
3. Effect of hemodilution with dextran, stroma-free hemoglobin solution and fluosol-DA on experimental myocardial ischemia in the dog.
Biro GP
Bibl Haematol; 1981; (47):54-69. PubMed ID: 6175307
[No Abstract] [Full Text] [Related]
4. Normothermic whole body rinse-out utilizing perfluorochemical(PFC)-containing artificial blood.
Agishi T; Yamagata K; Kobayashi M; Teraoka S; Honda H; Ota K
Trans Am Soc Artif Intern Organs; 1984; 30():295-7. PubMed ID: 6533899
[No Abstract] [Full Text] [Related]
5. Present status of clinical studies of Fluosol-DA (20%) in Japan.
Mitsuno T; Ohyanagi H
Int Anesthesiol Clin; 1985; 23(1):169-84. PubMed ID: 3980104
[TBL] [Abstract][Full Text] [Related]
6. Effect of Fluosol-DA on infarct morphology and vulnerability to ventricular arrhythmia.
Kolodgie FD; Dawson AK; Roden DM; Forman MB; Virmani R
Am Heart J; 1986 Dec; 112(6):1192-201. PubMed ID: 3788766
[TBL] [Abstract][Full Text] [Related]
7. [The place for using erythrocyte substitutes in hemodilution: fluosol-DA and polymerized pyridoxylated hemoglobin].
Vigneron C; Labrude P; Dellacherie E
Ann Fr Anesth Reanim; 1986; 5(3):260-8. PubMed ID: 3535579
[TBL] [Abstract][Full Text] [Related]
8. Red cell substitutes: hemoglobin solution or fluorocarbon?
Gould SA; Rosen AL; Sehgal LR; Sehgal HL; Rice CL; Moss GS
J Trauma; 1982 Sep; 22(9):736-40. PubMed ID: 7120525
[TBL] [Abstract][Full Text] [Related]
9. Development of a perfluorochemical whole blood substitute (Fluosol-DA, 20%)--an overview of clinical studies with 185 patients.
Suyama T; Yokoyama K; Naito R
Prog Clin Biol Res; 1981; 55():609-28. PubMed ID: 7027272
[TBL] [Abstract][Full Text] [Related]
10. Which is the foreseeable clinical application of oxygen-carrying blood substitutes (fluorocarbons and hemoglobin solutions)? Which impact are they likely to have on the activity of blood services?
Vox Sang; 1982 Feb; 42(2):97-109. PubMed ID: 7064434
[No Abstract] [Full Text] [Related]
11. Perfluorochemical emulsion oxygen transport fluids: a clinical review.
Tremper KK; Anderson ST
Annu Rev Med; 1985; 36():309-13. PubMed ID: 3888055
[TBL] [Abstract][Full Text] [Related]
12. A perfluorochemical emulsion as an oxygen carrier.
Yokoyama K; Suyama T; Okamoto H; Watanabe M; Ohyanagi H; Saitoh Y
Artif Organs; 1984 Feb; 8(1):34-40. PubMed ID: 6703924
[TBL] [Abstract][Full Text] [Related]
13. The effects of fetal exchange transfusion with a red blood cell substitute.
Ambrose A; Cefalo RC; Bowes WA
Am J Obstet Gynecol; 1986 Mar; 154(3):667-74. PubMed ID: 3082209
[TBL] [Abstract][Full Text] [Related]
14. Experimental studies on fluosol DA administration in acute pancreatitis.
Ohyanagi H; Ohashi O; Nakayama S; Yamamoto M; Okumura S; Saitoh Y
Biomater Artif Cells Artif Organs; 1988; 16(1-3):585-94. PubMed ID: 3179491
[TBL] [Abstract][Full Text] [Related]
15. Hemodynamic and oxygen transport effects of a perfluorochemical blood substitute, fluosol-DA (20%).
Tremper KK; Lapin R; Levine E; Friedman A; Shoemaker WC
Crit Care Med; 1980 Dec; 8(12):738-41. PubMed ID: 7449405
[TBL] [Abstract][Full Text] [Related]
16. Development of a perfluorochemical emulsion as a blood gas carrier.
Mitsuno T; Ohyanagi H; Yokoyama K
Artif Organs; 1984 Feb; 8(1):25-33. PubMed ID: 6422912
[TBL] [Abstract][Full Text] [Related]
17. Modification of cerebral ischemia with Fluosol.
Peerless SJ; Nakamura R; Rodriguez-Salazar A; Hunter IG
Stroke; 1985; 16(1):38-43. PubMed ID: 3966263
[TBL] [Abstract][Full Text] [Related]
18. Effects of a transfusion with a blood substitute (Fluosol-DA, 20%). Part II: Human cerebral blood flow.
Nagasawa S; Handa H; Yonekawa Y; Oda Y; Tsuda Y; Yokoyama K
Neurol Res; 1983; 5(2):19-30. PubMed ID: 6140661
[TBL] [Abstract][Full Text] [Related]
19. Recent studies on perfluorochemical (PFC) emulsion as an oxygen carrier in Japan.
Mitsuno T; Ohyanagi H; Yokoyama K; Suyama T
Biomater Artif Cells Artif Organs; 1988; 16(1-3):365-73. PubMed ID: 3052644
[TBL] [Abstract][Full Text] [Related]
20. Effect of Fluosol-DA (20%) on skin flap survival in rats.
Ramasastry SS; Waterman P; Angel MF; Futrell JW
Ann Plast Surg; 1985 Nov; 15(5):436-42. PubMed ID: 4083744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
